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Abstract Pulmonary hypertension (PH) is a severe com-
plication of sarcoidosis, with an unknown prevalence. The
aetiology is multifactorial, and the exact mechanism of PH
in the individual patient is often difficult to establish. The
diagnostic work-up and treatment of PH in sarcoidosis is
complex, and should therefore be determined by a multi-
disciplinary expert team in a specialised centre. It is still
a major challenge to identify sarcoidosis patients at risk for
developing PH. There is no validated algorithm when to
refer a patient suspected for PH, and PH analysis itself is
difficult. Until present, there is no established therapy for
PH in sarcoidosis. Besides optimal treatment for sarcoido-
sis, case series evaluating new therapeutic options involving
PH-targeted therapy are arising for a subgroup of patients.
This review summarises the current knowledge regarding
the aetiology, diagnosis and possible treatment options for
PH in sarcoidosis.
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Introduction
Sarcoidosis is a rare, multisystemic disorder of unknown
aetiology. It is characterised by non-caseating granulomas
which present in multiple tissues, particularly in the lung
and lymphatic system. The course of sarcoidosis can vary
from spontaneous resolution to severe and chronic disease.
It is often complicated by pulmonary fibrosis [1].
Pulmonary hypertension (PH) is defined as a mean pul-
monary artery pressure (PAP) of ≥25 mmHg at rest mea-
sured by right heart catheterisation [2]. PH is increas-
ingly recognised as a serious complication of pulmonary
sarcoidosis. The clinical diagnosis or suspicion of PH in
sarcoidosis is challenging, since symptoms overlap. PH
exists in all stages of sarcoidosis; however, the frequency
largely depends on the severity of the sarcoidosis [3, 4].
There is a lack of robust data on accurate diagnostic tools
and therapeutic options for PH in sarcoidosis. However,
diagnostic tests are in further development, and case series
of potential treatment options are arising. Diagnosis and
treatment decisions should be made in a specialised team,
including a dedicated cardiologist, pulmonologist, radiolo-
gist and nurse. In this review, we will discuss the classifi-
cation and aetiology of sarcoidosis-associated PH (SAPH),
diagnostic tests and possible treatment options.
Epidemiology
There are no clear data regarding the true prevalence of
SAPH. Rates of PH in sarcoidosis patients in tertiary cen-
tres vary between 5–20 % [3, 5, 6]. As a side note, the gold
standard right heart catheterisation for diagnosing PH is
often absent in studies, where results are based on echocar-
diography only. The prevalence of PH may increase to
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Tab. 1 Clinical classification of pulmonary hypertension [2]
WHO group 1 Pulmonary arterial hypertension
WHO group 2 Pulmonary hypertension due to left heart disease
WHO group 3 Pulmonary hypertension due to lung disease and/or hypoxaemia
WHO group 4 Chronic thromboembolic pulmonary hypertension or other pulmonary artery obstructions
WHO group 5 Pulmonary hypertension with unclear multifactorial mechanism
5.1 Hematologic disorders: myeloproliferative disorders, splenectomy, chronic haemolytic disorders
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis lymphangioleiomyomatisos
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
5.4 Others: pulmonary tumoral thrombotic microangiopathy, fibrosing mediastinitis, chronic renal failure,
segmental pulmonary hypertension
WHO World Health Organisation
> 50 % in sarcoidosis patients with persistent or unex-
plained dyspnoea [4, 7]. A PH prevalence of more than
70 % was found in sarcoidosis patients awaiting lung trans-
plant [8, 9].
Prognosis
Mortality in sarcoidosis patients is significantly increased
if PH is present, independent of pulmonary function [10,
11]. For 22 patients with haemodynamically confirmed
SAPH, the 1-, 2-, and 5-year survival was found to be 84,
74 and 59 %, compared with 100, 96 and 96 % in matched
sarcoidosis patients without PH (p = 0.003) [10]. Another,
non-invasive study showed an echocardiographic estimation
of systolic PAP >50 mmHg to be associated with increased
mortality [7].
Classification of PH in sarcoidosis
According to the World Health Organisation, PH is clas-
sified into five different groups, based on clinical presen-
tation, pathological findings, haemodynamic characteristics
and treatment strategy (Tab. 1; [2]). SAPH is classified in
group 5: PH with an unknown and multifactorial mech-
anism. However, PH in sarcoidosis can be classified in
group 2, 3 or 4 as well, if the underlying mechanism is
clear. For example, a patient with severe fibrotic abnormal-
ities with a mean PAP that is in line with the severity of
the lung disease will be classified as group 3 PH. On the
other hand, if a patient presents with mild lung disease, but
the mean PAP is high (e. g. >35 mmHg), a component of
vasculopathy can be suspected. The haemodynamic profile
might show similarities with pulmonary arterial hyperten-
sion. Because of the unknown mechanism, this patient will
be classified as group 5 PH.
Aetiology of PH in sarcoidosis
The aetiology of PH in sarcoidosis is multifactorial. Based
on the pulmonary artery wedge pressure (PAWP), SAPH
can be divided into pre-capillary (PAWP ≤15 mmHg) and
post-capillary (PAWP >15 mmHg) PH [2].
Pre-capillary PH
Pre-capillary PH in sarcoidosis might be due to one or sev-
eral mechanisms. Hypothesised mechanisms are described
below.
Destruction of distal capillary bed and resultant
hypoxaemia
Hypoxic vasoconstriction due to destruction of the distal
capillary bed is one of the first possible mechanisms of
SAPH. Data to support this mechanism are scarce, ranging
from no difference in oxygen saturation or need for sup-
plemental oxygen between sarcoidosis patients with and
without PH [4], to the need of supplemental oxygen as
only predictor of SAPH in patients listed for lung trans-
plantation [8]. The majority of patients with SAPH suffer
a more advanced stage of sarcoidosis, often in the presence
of pulmonary fibrosis [3, 5, 7, 10]. However, approximately
32–50 % of the patients with SAPH have no significant fi-
brosis [3, 5, 10], suggesting that fibrotic ablation of the
pulmonary vasculature is not the only mechanism to ex-
plain SAPH.
Specific vasculopathy
Involvement of granulomatous vasculopathy is another
possible mechanism of SAPH [12]. One study reported
vascular involvement in all 40 autopsies of patients with
mainly pulmonary and cardiac sarcoidosis [13]. Granulo-
matous vasculopathy causes frequent occlusion of arterioles
or venules [13] and angiitis [14], which might result in PH.
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Fig. 1 Compression of the
pulmonary artery. A case
of a 60-year-old female with
stage IV sarcoidosis, diagnosed
with PH with a mean PAP of
63 mmHg, due to compres-
sion of the pulmonary artery.
a Compression on chest CT;
b Pulmonary angiogram of the
left lobe
Sarcoid granulomas can be found throughout all layers of
the pulmonary vascular wall, often in combination with in-
timal fibrosis, medial proliferation, inflammatory changes,
necrosis and destruction of the small-vessel architecture,
which leads to an occlusive vasculopathy [10, 13]. Granu-
lomas can also be formed at the level of the intima in large
vessels. These patients are often misclassified as having
chronic thromboembolic pulmonary hypertension.
Local increased vasoreactivity
Acute vasoresponsiveness is defined as a decrease in mean
PAP of ≥10 mmHg to an absolute value of mean PAP
≤40 mmHg, with an increased or unchanged cardiac output
[2]. Several patients with SAPH have shown responsive-
ness to acute vasodilator challenge with inhaled nitrogen
oxide or prostacyclin. Preston et al. [15] showed a de-
crease of 18 ± 4 % in mean PAP and 31 ± 5 % in pul-
monary vascular resistance in seven of eight patients re-
ceiving inhaled nitric oxide, with a slight increase of car-
diac output. For epoprostenol, no significant change was
reported. Fisher et al. [16] showed an average decrease
in pulmonary vascular resistance of 45 %, and a non-sig-
nificant decrease in mean PAP of 11 % in six out of seven
patients using epoprostenol. However, an increased vasore-
activity is not a predictor for response to PH-targeted ther-
apy in pulmonary arterial hypertension, but highlights the
potential role of an increased reactivity of the pulmonary
vasculature as part of the unclear pathogenesis of PH in
sarcoidosis.
Extrinsic compression of pulmonary vessels
Extrinsic compression of the pulmonary arteries, and less
frequently the pulmonary veins, by enlarged lymph nodes or
fibrosing mediastinitis, has also been described as a mech-
anism for SAPH [10, 13, 17]. Fig. 1 shows an example
of a sarcoidosis patient with PH due to compression of the
pulmonary artery. Compression of the pulmonary artery oc-
curs more frequently in chronic sarcoidosis, and presented
in 21 % of the PH patients with radiographic stage IV sar-
coidosis [10].
Portal hypertension
Hepatic sarcoidosis is present in up to 70 % of sarcoidosis
patients, and might lead to PH due to cirrhosis and portal
hypertension [18]. Approximately 1–5 % of patients with
portal hypertension develop PH [2], with liver cirrhosis be-
ing the most common cause of portal hypertension.
Pulmonary veno-occlusive disease
Pulmonary veno-occlusive disease is defined as extensive
narrowing or occlusion of the pulmonary veins in lobu-
lar septa or intra-acinar venules by fibrous tissue [19]. In
a case series of five patients with SAPH who underwent
lung transplant, all explanted lungs demonstrated presence
of pulmonary veno-occlusive disease [10].
Post-capillary PH
Apart from pre-capillary PH, post-capillary PH can also
be found in sarcoidosis. Systolic, diastolic and subclinical
left ventricular dysfunction are often present in sarcoidosis
[20]. In a retrospective study consisting of 130 sarcoido-
sis patients of all stages, with persistent moderate to se-
vere dyspnoea, who underwent right heart catheterisation
after at least six months of immunosuppressive therapy, the
prevalence of PH was 54 %. Interestingly, in 29 % an el-
evated PAWP >15 mmHg was measured, suggesting left
ventricular disease as a cause of PH [7]. Left ventricular
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Fig. 2 Measurement of the
pulmonary artery on chest CT.
a Measurement of the main
pulmonary artery, at the level
of the bifurcation along the line
that originates from the centre
of the adjacent ascending aorta,
perpendicular to the axis of main
pulmonary artery; b If the trunk
is too curved, measurements can
be made using the other method
[32]
dysfunction might be due to myocardial involvement of sar-
coidosis. Autopsy studies suggest that at least 25 % of the
patients with sarcoidosis have myocardial involvement. The
diagnosis of cardiac sarcoidosis is difficult, because signs
and symptoms can be subtle or even absent. The expert
consensus statement advises to screen for cardiac sarcoido-
sis using cardiac magnetic resonance imaging (CMR) and
18 F-fluorodeoxyglucose positron emission tomography in
sarcoidosis patients at risk for myocardial involvement [21].
Diagnosis
Establishing the diagnosis of PH in sarcoidosis is challeng-
ing. Symptoms suggestive for PH are dyspnoea, dizziness,
cough and chest pain, or signs such as elevated jugular
venous pressure, S3 or S4 heart sounds, lower extremity
oedema or right ventricular heave. These signs are usu-
ally associated with more advanced PH [4]. During follow-




Several parameters of pulmonary function testing are asso-
ciated with SAPH, such as a decreased forced vital capacity,
total lung capacity [5] and decreased diffusion capacity of
carbon monoxide [3]. However, PH also occurs in sar-
coidosis patients with near-normal lung function tests. An
echocardiographic study reports a prevalence of PH of 28 %
in 127 sarcoidosis patients with near-normal lung function
tests, defined as a forced vital capacity >70 %, forced expi-
ratory volume in 1 second >70 %, and diffusion capacity of
carbon monoxide >60 % [22]. Therefore, PH is suspected
in the presence of progressive dyspnoea, while pulmonary
function tests remain stable.
Exercise testing
The 6-minute walk test (6MWT) can also raise suspicion for
PH. Most sarcoidosis patients with PH will have a 6MWT
distance of less than 450 meters [3, 23–27]. An oxygen
desaturation to a value below 90 % during the 6MWT is
associated with PH [3]. However, a major limitation of the
6MWT is that results may be influenced by other factors,
such as airway disease, cardiac disease, fatigue and muscle
involvement [27].
Cardiopulmonary exercise testing for detecting PH has
not been studied systematically in sarcoidosis. In patients
with pulmonary arterial hypertension, reduced maximum
oxygen uptake (VO2max), increased ventilator inefficiency,
early lactate acidosis, decreased end-expiratory CO2 and
reduced O2 pulse are an indication for pulmonary arte-
rial hypertension, although these parameters are non-spe-
cific [28]. One study evaluated exercise testing in patients
with interstitial lung disease. Peak exercise capacity was
significantly lower in interstitial lung disease patients with
PH compared with those without PH. Also, carbon dioxide
production and load (Watts) was lower, and the ventilation/
carbon dioxide production ratio at ventilatory threshold was
higher in patients with PH [29].
Chest computed tomography
A dilated pulmonary artery on chest computed tomography
(CT) may raise suspicion of PH [2]. The cut-off value is
≥29 mm for the pulmonary artery, or a ratio of the pul-
monary artery diameter to the ascending aorta diameter of
≥1 [2]. Fig. 2 shows the measurement of the pumonary
artery diameter on chest CT. Two studies [30, 31] found no
correlation between the pulmonary artery diameter and the
mean PAP in patients with fibrotic lung disease. However,
a recently published article investigating only sarcoidosis
patients [32], showed a good correlation for the pulmonary
artery diameter indexed for body surface area and the pres-
ence of PH; this had a high diagnostic accuracy for discrimi-
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Tab. 2 Echocardiographic probability of pulmonary hypertension in symptomatic patients with a suspicion of PH [2]
Echocardiographic pulmonary hyperten-
sion probability
Peak tricuspid regurgitation velocity
(m/s)
Other signsa for pulmonary hypertension on
echocardiography
Low ≤2.8 or not measurable No




aOther signs are described in Tab. 3. To meet the criteria of other signs, at least two other signs of at least two different categories must be
abnormal
Tab. 3 Echocardiographic signs suggestive for pulmonary hypertension [2]
The ventricles Right ventricle/left ventricle basal diame-
ter ratio >1.0
Flattening of the interventricular septum
(left ventricular eccentricity index >1.1 in
systole and/or diastole)
Pulmonary artery Pulmonary arterial acceleration time <105
msec and/or midsystolic notching




Inferior vena cava and right
atrium
Inferior cava diameter >21 mm with de-
creased inspiratory collapse (<50 % with
a sniff or <20 % with quiet inspiration)
Right atrial area (end-systole >18 cm2)
PA pulmonary artery, PH pulmonary hypertension
nating between the presence and absence of PH. Other chest
CT parameters are right ventricular enlargement, or a seg-
mental artery:bronchus ratio > 1:1. However, they seem to
have less value in clinical practice.
Cardiac magnetic resonance imaging
CMR is often used for detecting cardiac sarcoidosis. In
case of suspicion of PH, CMR is a valuable tool to ac-
curately and reproducibly assess the right ventricular di-
mension, morphology and function, stroke volume, cardiac
output, pulmonary artery distensibility and right ventricular
mass. Reduced pulmonary artery distensibility and retro-
grade flow are predictive for PH in patients at risk; however,
this cannot exclude PH [33].
Specific PH analysis
In general, the PH analysis protocol used in sarcoidosis
patients is similar to the standard analysis protocol as de-
scribed in the PH guideline [2]. The analysis consists of
biomarkers, electrocardiogram (ECG) and echocardiogra-
phy.
Biomarkers
The main biomarker for PH is brain natriuretic peptides
(BNP). Recently, BNP has been studied in a right heart
catheterisation study of a group of 113 patients with inter-
stitial lung disease [34]. BNP was significantly increased
in patients with an invasive systolic PAP >40 mmHg. How-
ever, BNP levels were significantly higher in patients with
an increased PAWP. The correlation between BNP and the
mean PAP was strong (r = 0.82, p < 0.001).
Electrocardiogram
Abnormalities on the ECG suggesting right ventricular
overload often present in more severe PH. Therefore, ECG
cannot be used to exclude the diagnosis. ECG abnor-
malities include P-pulmonale, right axis deviation, right
ventricular hypertrophy or strain, right bundle branch block
and QTc prolongation [2].
Echocardiography
Echocardiography plays a key role in PH analysis [2]. The
primary echocardiographic parameter for PH is the estima-
tion of the systolic PAP based on the peak tricuspid re-
gurgitation velocity (TRV) measured by continuous wave
Doppler and the right atrial pressure [2]. Importantly, this
measurement can overestimate or underestimate the actual
pressures. A meta-analysis of 29 studies showed a mod-
est diagnostic accuracy [35]. However, the accuracy drops
if the tricuspid regurgitation jet is difficult to obtain, and if
image quality is limited. Therefore, isolated use of the peak
TRV is unreliable. Recently, the guidelines recommend us-
ing peak TRV in combination with additional parameters in
order to divide patients according to the echocardiographic
probability of PH [2]. Additional parameters include for
example right ventricular dilatation and/or hypertrophy, de-
creased systolic right ventricular function by assessing tri-
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Fig. 3 Flow chart for pul-
monary hypertension screening
in sarcoidosis
cuspid annulus plane systolic excursion and S-wave on tis-
sue Doppler imaging, pulmonary artery dilation, right atrial
dilation, and pulmonary artery acceleration time [2]. The
echocardiographic signs and subsequent classifications are
summarised in Tab. 2 and 3.
The literature on echocardiographic findings in sarcoido-
sis patients is scarce, and the value of right ventricular sys-
tolic pressure and peak TRV is controversial. In patients
with interstitial lung disease including pulmonary fibrosis,
right ventricular systolic pressure was found to be less ac-
curate and measurable in only 54 % of the patients [36,
37]. In an echocardiographic study of 80 sarcoidosis pa-
tients, TRV was measurable in 70 % of patients. There was
a significant correlation (r = 0.62, p < 0.0001) between the
non-invasive and invasive measurements. However, several
patients could have been misclassified [7].
A benefit of echocardiography is the possibility to detect
other cardiac abnormalities to explain dyspnoea. Besides
PH, the right ventricular function is also associated with
cardiac sarcoidosis and abnormal pulmonary function tests,
and might even be an isolated finding [38].
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Tab. 4 Overview of literature on pulmonary hypertension targeted treatment in sarcoidosis
Author Year and
type
Treatment N mPAP PVR CO Other outcomes and adverse
events
Prostacyclin analogues
Preston [15] 2001 CS Nitric oxide 8 ↓ 18 % ↓ 31 % ↑ 12 %
Preston [15] 2001 CS Epoprostenol 6 ↔ ↓ 25 % ↑ 25 %
Fisher [16] 2006 CS Epoprostenol 7 ↓ 21 % ↓ 45 % ↑ 44 % ↑ NYHA 1–2 classes
Decreased Pao2 in 3/7
One death
Baughman [45] 2009 CS Iloprost 15 ↓ 15 % ↓ 45 % – ↑ 12 % 6MWT
↑ QOL
Decrease in Pao2 in 2/15
Endothelin receptor antagonists
Judson [46] 2011 CS Ambrisentan 21 – – – ↔ 6MWT, NYHA, QOL
38 % discontinued due to
↑ oedema and dyspnoea
Baughman [26] 2014 RCT Bosentan 35 ↓ 11 % ↓ 28 % – ↔ 6MWT
Phosphodiesterase 5 inhibitors
Milman [9] 2008 CS Sildenafil 12 ↓ 19 % ↓ 48 % ↑ 36 % ↔ 6MWT
Combined studies
Barnett [25] 2009 CS Sildenafil, bosen-
tan, epoprostenol
22 ↓ 20 % ↓ 39 % ↔ ↑ 6MWT
Dobarro [47] 2013 CS Bosentan (2) or
sildenafil (9)
11 ↔ ↔ ↔ ↑ 6MWT
↔ NYHA
6MWT six-minute walk test, CO cardiac output, CS case series, mPAP mean pulmonary artery pressure, NYHA New York Heart Association,
PaO2 partial arterial oxygen pressure, PVR pulmonary vascular resistance, QoL quality of life, RCT randomised controlled trial
Right heart catheterisation
Right heart catheterisation remains the gold standard for
diagnosing PH [2]. The invasive nature of this diagnostic
modality makes it unsuitable for routine use [39]. Right
heart catheterisation is recommended in patients with an
intermediate or high risk of PH, on echocardiography, with
realistic treatment possibilities [2]. The mean PAP in pa-
tients awaiting lung transplantation was 9 mmHg higher in
sarcoidosis patients compared with idiopathic pulmonary fi-
brosis, despite similar spirometric severity [40]. In patients
with sarcoidosis, PAPs are often higher than expected by
parenchymal involvement only [40]. In such cases, a mean
PAP exceeding 35 mmHg has to be considered to be severe
PH. Additional to interstitial lung disease, these patients are
suspected for pulmonary vascular abnormalities [41].
Recommendations for clinical practice
The literature regarding PH in sarcoidosis is scarce. There-
fore, it is difficult to make evidence-based and clear recom-
mendations as to which patients are at risk of developing
PH, and on the best method for screening. Based on the
current literature, we constructed a flow chart to give some
guidance for screening (Fig. 3). Importantly, patients with
intermediate to high risk for PH should be referred to a PH
centre for further analysis.
Management
In PH, a multidisciplinary approach involving cardiologists,
pulmonologists and radiologists specialised in PH and in-
terstitial lung disease is mandatory. Treatment of PH in sar-
coidosis has only been studied in small groups, and there
is no solid proof for the use of PH-targeted therapy in sar-
coidosis. Therefore, treatment might benefit the individual
patient, but there is no evidence for effectiveness. The treat-
ment goal is to improve the vascular, haemodynamic and
functional outcomes. Suggested therapies are targeted to
the underlying mechanisms of PH in sarcoidosis. These
strategies can be divided into sarcoidosis-targeted treat-
ment and PH-targeted treatment. Both strategies will be
described below.
Sarcoidosis-targeted treatment
Sarcoidosis-targeted treatment might be indicated if the
mechanism of PH is suspected to be due to sarcoidosis
itself, for example in patients with compression of the pul-
monary artery by lymphadenopathy. There is a step-wise
approach for the management of sarcoidosis [42]. First-
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line treatment of sarcoidosis consists of oral glucocorti-
coids. However, long-term use on high doses is associated
with substantial morbidity. As an alternative, antimetabo-
lites such as methotrexate and azathioprine might be used.
The next step would be anti-tumour necrosis factor mono-
clonal antibodies, or rituximab [42].
Anti-inflammatory and immunomodulatory agents
Anti-inflammatory and immunomodulatory agents poten-
tially improve PH, if caused by active granulomatous in-
flammation. Nunes et al. [10] evaluated ten sarcoidosis
patients (one with stage 0, four with stage II, and five with
stage IV) after treatment with high doses of glucocorticos-
teroids. Patients with stage IV sarcoidosis did not respond,
whereas in three patients (one with stage 0 and two with
stage II) systolic PAP decreased by more than 20 % after
3–6 months of follow-up. Afterwards, these patients were
maintained on low doses of corticosteroids, and the sys-
tolic PAP continued to decrease. This suggests that fibrotic
disease is most likely not responsive to corticosteroids,
whereas patients with active granulomatous inflammation
might benefit. Patients with compression of the pulmonary
artery due to enlarged lymph nodes might also benefit from
immunosuppressive treatment [10].
Oxygen therapy
Hypoxic vasoconstriction due to decreased arterial oxygen
pressure is one of the possible mechanisms for PH. Oxygen
therapy is recommended in a subgroup of patients. Oxygen
administration was shown to reduce pulmonary vascular
resistance in patients with pulmonary arterial hypertension;
however, there are no randomised data for long-term oxy-
gen therapy [2]. Based on a study in patients with chronic
obstructive pulmonary disease, the European guidelines for
PH recommend the use of oxygen in patients with a partial
arterial blood oxygen pressure < 8.0 kPa [2].
PH-targeted therapy
PH-targeted therapy is reserved for group 1 and 4 PH pa-
tients only. Over the last years, treatment of SAPH using
the PH-targeted therapy carefully shows some improvement
in selected patients, especially in the presence of specific
vasculopathy or increased vasoreactivity. This is based
on case series only. Due to the lack of randomised con-
trolled clinical trials and potential severe adverse events
of treatment, the use of PH-targeted therapy in sarcoidosis
is currently off-label. It should be noted that PH-targeted
therapy can be ineffective and sometimes even dangerous
for patients with fibrotic remodelling. These patients are
less likely to respond to vasodilators, and treatment might
worsen oxygenation, since the physiological hypoxaemic
vasoconstriction is inhibited. As a result, there is an in-
creased blood flow to areas with poor ventilation that might
lead to a shunt or ventilation/perfusion discrepancy, as de-
scribed in patients with idiopathic pulmonary fibrosis [43].
Therefore, significant hypoxia can be a contraindication for
PH-targeted treatment. It may also cause acute pulmonary
oedema and hypoxaemia through preferential vasodilation
of the pulmonary arteries, if there is a down-stream venular
obliteration by granulomas [16]. Therefore, treating physi-
cians should be very careful before initiating these drugs in
sarcoidosis patients, and treatment decisions should only be
made on an individual basis in an expert centre by a multi-
disciplinary team, based on a goal-oriented approach with
predefined targets.
Below, the PH-targeted therapies in SAPH will be dis-
cussed. Outcomes of the most important studies are sum-
marised in Tab. 4.
Prostacyclin analogues
During the 1980s, prostanoids were the first agents used in
an attempt to treat PH in sarcoidosis [44]. Decades later,
a case series appeared evaluating epoprostenol for moderate
to severe PH in eight sarcoidosis patients [16]. Most pa-
tients responded. One patient, with pulmonary veno-occlu-
sive disease as an underlying mechanism of PH, developed
congestive heart failure leading to pulmonary oedema. In
a study of 15 patients with inhaled iloprost [45], six had
improved haemodynamics and significant improvement in
quality of life. As a clinical outcome, only three patients
had more than 30 m improvement in their 6MWT.
Endothelin receptor antagonists
Endothelin receptor antagonists have been more exten-
sively investigated, particularly bosentan. One double-
blind, placebo-controlled trial investigated 35 PH patients
with all different sarcoidosis stages, presenting with New
York Heart Association class II or III symptoms, low
PAWP and stable on immunosuppressive therapy for at
least three months [26]. Bosentan improved the mean
PAP and pulmonary vascular resistance. However, this 16-
week period of treatment did not significantly improve the
6MWT or quality of life. A prospective case series of
21 sarcoidosis patients of all stages studied ambrisentan,
another endothelin receptor antagonist. This resulted in
preliminary cessation of treatment in > 50 % of the patients
[46], mainly due to oedema and/or dyspnoea. The ten
patients who completed the study seemed to have an im-
proved quality of life. However, the study was not powered
to have significant results. There are no data regarding the
outcomes of macitentan for treating PH in sarcoidosis.
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Phosphodiesterase 5 inhibitors
Milman and colleagues [9] reported improvement in the
haemodynamics in patients with PH awaiting lung trans-
plant, treated with sildenafil. There was no change in the
6MWT distance. Some cases suggest phosphodiesterase 5
inhibitors to be more successful in treating sarcoidosis pa-
tients with less severe PH [25, 47].
Lung transplant
For patients with end-stage pulmonary parenchymal sar-
coidosis or SAPH who failed therapy, single or bilateral
lung transplant can be a feasible option. Between Jan-
uary 1995 and June 2012, 954 sarcoidosis patients out of
18 countries underwent lung transplant [48]. Median sur-
vival for sarcoidosis patients after lung transplant is calcu-
lated to be approximately 8.5 years [48].
Conclusion
Sarcoidosis patients have an increased risk of developing
PH. The exact prevalence of PH in sarcoidosis is unknown.
To date, identifying sarcoidosis patients at risk for PH is
still a major challenge. There is no validated algorithm to
refer patients for PH analysis, which might lead to under-
detection of PH. Moreover, echocardiography has limited
diagnostic accuracy, especially in patients with parenchy-
mal involvement. More extensive diagnostic tests and eval-
uation of treatment possibilities should therefore be consid-
ered in specialised centres with a multidisciplinary expert
team. Treatment of PH in sarcoidosis is challenging, since
there is a lack of robust data. Case series evaluating treat-
ment options involving PH-targeted therapy are arising for
a subgroup of patients. Therefore, further research aiming
to optimise the diagnostics and treatment for PH in pul-
monary sarcoidosis is warranted.
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